Mylan's Latest Focalin ANDA Brings Novartis IP Suit

By Aaron Taube (December 14, 2012, 3:53 PM EST) -- Celgene Corp. and Novartis Pharma AG has slapped Mylan Pharmaceuticals Inc. with a lawsuit in New Jersey federal court alleging the generic and specialty pharmaceutical company violated six of their patents when it applied to produce new versions of the attention deficit hyperactivity disorder drug Focalin XR....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!